Table 6.

Basic information of included patients from our hospital diagnosed in 2003–2019 after PSM

Variables	Total	Early-onset GSRCC	Late-onset GSRCC	P value
Total	70	35	35
Sex				1
Male	40 (57.14%)	20 (57.14%)	20 (57.14%)
Female	30 (42.86%)	15 (42.86%)	15 (42.86%)
Smoke				0.255
Never	54 (77.14%)	29 (82.86%)	25 (71.43%)
Yes	16 (22.86%)	6 (17.14%)	10 (28.57%)
Primary site				0.4
Cardia	3 (4.29%)	1 (2.85%)	2 (5.71%)
Fundus	3 (4.29%)	1 (2.85%)	2 (5.71%)
Antrum	42 (60%)	19 (54.28%)	23 (65.71%)
Body	20 (28.57%)	13 (37.14%)	7 (20%)
Overlappping/NOS	2 (2.86%)	1 (2.85%)	1 (2.85%)
T stage				0.576
T1	8 (11.43%)	4 (11.43%)	4 (11.43%)
T2	10 (14.28%)	5 (14.29%)	5 (14.29%)
T3	10 (14.28%)	7 (20%)	3 (8.57%)
T4	42 (60%)	19 (54.28%)	23 (65.71%)
N stage				0.63
N0	139 (34.49%)	9 (25.71%)	8 (22.86%)
N1	60 (14.89%)	2 (5.71%)	5 (14.29%)
N2	19 (27.14%)	9 (25.71%)	10 (28.57%)
N3	27 (72.86%)	15 (42.86%)	12 (34.29%)
M stage				0.045
M0	59 (84.29%)	26 (74.29%)	33 (94.29%)
M1	11 (15.71%)	9 (25.71%)	2 (5.71%)
Lesion classification				0.689
Infiltration type	6 (8.57%)	4 (11.43%)	2 (5.71%)
Ulcerative type	52 (74.29%)	25 (71.43%)	27 (77.14%)
Protuberant type	12 (17.14%)	6 (17.14%)	6 (17.14%)
Lymphatic vessel invasion				0.621
No	26 (37.14%)	12 (34.29%)	14 (40%)
Yes	44 (62.86%)	23 (65.71%)	21(60%)
Tumor size				0.203
≤ 2 cm	22 (31.43%)	8 (22.86%)	14 (40%)
≤ 5 cm	33 (47.14%)	20 (57.14%)	13 (37.14%)
> 5 cm	15 (21.43%)	7 (20%)	8 (22.86%)
Examined LNs				0.495
≤ 16	10 (14.29%)	6 (17.14%)	4 (11.43%)
> 16	60 (85.71%)	29 (82.86%)	31 (88.57%)
Chemotherapy				1
No	38 (54.29%)	19 (54.29%)	19 (54.29%)
Yes	32 (45.71%)	16 (45.71%)	16 (45.71%)